Allogene Therapeutics Total Liabilities and Share Holders Equity 2018-2025 | ALLO

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Allogene Therapeutics total liabilities and share holders equity from 2018 to 2025. Total liabilities and share holders equity can be defined as the total of all liabilities and shareholders' equity.

Allogene Therapeutics Total Liabilities and Share Holders Equity 2018-2025 | ALLO

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Allogene Therapeutics total liabilities and share holders equity from 2018 to 2025. Total liabilities and share holders equity can be defined as the total of all liabilities and shareholders' equity.

Related Stocks
Company Name	Market Cap
AstraZeneca (AZN)	$209.6B
Amgen (AMGN)	$149.1B
Gilead Sciences (GILD)	$130.2B
Vertex Pharmaceuticals (VRTX)	$125.6B
Bristol Myers Squibb (BMY)	$100.2B
CSL (CSLLY)	$74.3B
GSK (GSK)	$74.1B
Regeneron Pharmaceuticals (REGN)	$61.6B
Argenex SE (ARGX)	$36.2B
Alnylam Pharmaceuticals (ALNY)	$30.5B
BioNTech SE (BNTX)	$23.7B
BeiGene (ONC)	$22.8B
Biogen (BIIB)	$17.4B
Genmab (GMAB)	$13.3B
Genmab (GNMSF)	$13.3B
Insmed (INSM)	$13.2B
BioMarin Pharmaceutical (BMRN)	$11.3B
Illumina (ILMN)	$11.3B
Incyte (INCY)	$11.3B
Ascendis Pharma (ASND)	$10.1B
Exelixis (EXEL)	$10B
Swedish Orphan Biovitrum (BIOVF)	$9.6B
Moderna (MRNA)	$9.6B
QIAGEN (QGEN)	$9B
Exact Sciences (EXAS)	$7.7B
Bio-Techne Corp (TECH)	$7.6B
Repligen (RGEN)	$7.3B
Halozyme Therapeutics (HALO)	$7.3B
Roivant Sciences (ROIV)	$7.2B
Revolution Medicines (RVMD)	$6.8B